drugset / Trial / NCT07452692

A Study to Assess the Skin Irritation and Sensitization of Selegiline TDS in Healthy Subjects

NCT07452692

Phase 1 Not yet recruiting 230 enrolled Corium Innovations, Inc.
RandomizedSingle-groupSingle-blindOther

Summary

The two products used in this study are transdermal patches that contain selegiline. The test drug is the Selegiline Transdermal Delivery System (TDS). The comparator drug is the EMSAM® TDS. The purpose of this research study is to compare how the skin tolerates the test TDS and the comparator TDS. The study will evaluate and compare skin irritation and possible allergic-type skin reactions (sensitization) caused by the two products. The comparison will be based on how the skin responds to repeated applications of each TDS. This includes the assessment of skin irritation during the Induction Period and the evaluation of possible allergic or sensitization reactions after the Challenge Period. In addition, the adhesion of each patch (how well the patch sticks to the skin over time) will be regularly checked, as this is important for both product performance and skin safety.

Timeline

Start
2026-07-01
Primary completion
2026-10-07
Completion
2026-10-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Selegiline Unknown 6 mg Other